Literature DB >> 32140262

The role of ubiquitination in tumorigenesis and targeted drug discovery.

Lu Deng1, Tong Meng2, Lei Chen3, Wenyi Wei4, Ping Wang5.   

Abstract

Ubiquitination, an important type of protein posttranslational modification (PTM), plays a crucial role in controlling substrate degradation and subsequently mediates the "quantity" and "quality" of various proteins, serving to ensure cell homeostasis and guarantee life activities. The regulation of ubiquitination is multifaceted and works not only at the transcriptional and posttranslational levels (phosphorylation, acetylation, methylation, etc.) but also at the protein level (activators or repressors). When regulatory mechanisms are aberrant, the altered biological processes may subsequently induce serious human diseases, especially various types of cancer. In tumorigenesis, the altered biological processes involve tumor metabolism, the immunological tumor microenvironment (TME), cancer stem cell (CSC) stemness and so on. With regard to tumor metabolism, the ubiquitination of some key proteins such as RagA, mTOR, PTEN, AKT, c-Myc and P53 significantly regulates the activity of the mTORC1, AMPK and PTEN-AKT signaling pathways. In addition, ubiquitination in the TLR, RLR and STING-dependent signaling pathways also modulates the TME. Moreover, the ubiquitination of core stem cell regulator triplets (Nanog, Oct4 and Sox2) and members of the Wnt and Hippo-YAP signaling pathways participates in the maintenance of CSC stemness. Based on the altered components, including the proteasome, E3 ligases, E1, E2 and deubiquitinases (DUBs), many molecular targeted drugs have been developed to combat cancer. Among them, small molecule inhibitors targeting the proteasome, such as bortezomib, carfilzomib, oprozomib and ixazomib, have achieved tangible success. In addition, MLN7243 and MLN4924 (targeting the E1 enzyme), Leucettamol A and CC0651 (targeting the E2 enzyme), nutlin and MI-219 (targeting the E3 enzyme), and compounds G5 and F6 (targeting DUB activity) have also shown potential in preclinical cancer treatment. In this review, we summarize the latest progress in understanding the substrates for ubiquitination and their special functions in tumor metabolism regulation, TME modulation and CSC stemness maintenance. Moreover, potential therapeutic targets for cancer are reviewed, as are the therapeutic effects of targeted drugs.
© The Author(s) 2020.

Keywords:  Cancer metabolism; Cancer microenvironment; Cancer stem cells; Cancer therapy

Year:  2020        PMID: 32140262      PMCID: PMC7048745          DOI: 10.1038/s41392-020-0107-0

Source DB:  PubMed          Journal:  Signal Transduct Target Ther        ISSN: 2059-3635


  524 in total

1.  Tumour suppression: disruption of HAUSP gene stabilizes p53.

Authors:  Jordan M Cummins; Carlo Rago; Manu Kohli; Kenneth W Kinzler; Christoph Lengauer; Bert Vogelstein
Journal:  Nature       Date:  2004-04-01       Impact factor: 49.962

2.  Triggering Fbw7-mediated proteasomal degradation of c-Myc by oridonin induces cell growth inhibition and apoptosis.

Authors:  Hui-Lin Huang; Heng-You Weng; Lu-Qin Wang; Chun-Hong Yu; Qiao-Juan Huang; Pan-Pan Zhao; Jun-Zhi Wen; Hui Zhou; Liang-Hu Qu
Journal:  Mol Cancer Ther       Date:  2012-03-02       Impact factor: 6.261

3.  Putting the parkin into Parkinson's.

Authors:  R L Nussbaum
Journal:  Nature       Date:  1998-04-09       Impact factor: 49.962

4.  Structures of CYLD USP with Met1- or Lys63-linked diubiquitin reveal mechanisms for dual specificity.

Authors:  Yusuke Sato; Eiji Goto; Yuri Shibata; Yuji Kubota; Atsushi Yamagata; Sakurako Goto-Ito; Keiko Kubota; Jun-ichiro Inoue; Mutsuhiro Takekawa; Fuminori Tokunaga; Shuya Fukai
Journal:  Nat Struct Mol Biol       Date:  2015-02-16       Impact factor: 15.369

Review 5.  Ubiquitination and SUMOylation in the chronic inflammatory tumor microenvironment.

Authors:  Shu Chun Chang; Jeak Ling Ding
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2018-08-21       Impact factor: 10.680

6.  Differential binding of p53 and nutlin to MDM2 and MDMX: computational studies.

Authors:  Thomas Leonard Joseph; Arumugam Madhumalar; Christopher J Brown; David P Lane; Chandra S Verma
Journal:  Cell Cycle       Date:  2010-03-15       Impact factor: 4.534

7.  Bortezomib arrests the proliferation of hepatocellular carcinoma cells HepG2 and JHH6 by differentially affecting E2F1, p21 and p27 levels.

Authors:  Daniele Baiz; Gabriele Pozzato; Barbara Dapas; Rossella Farra; Bruna Scaggiante; Mario Grassi; Laura Uxa; Carlo Giansante; Cristina Zennaro; Gianfranco Guarnieri; Gabriele Grassi
Journal:  Biochimie       Date:  2008-11-12       Impact factor: 4.079

Review 8.  Targeting the phosphoinositide 3-kinase pathway in cancer.

Authors:  Pixu Liu; Hailing Cheng; Thomas M Roberts; Jean J Zhao
Journal:  Nat Rev Drug Discov       Date:  2009-08       Impact factor: 84.694

9.  UBE2S elongates ubiquitin chains on APC/C substrates to promote mitotic exit.

Authors:  Mathew J Garnett; Jörg Mansfeld; Colin Godwin; Takahiro Matsusaka; Jiahua Wu; Paul Russell; Jonathon Pines; Ashok R Venkitaraman
Journal:  Nat Cell Biol       Date:  2009-10-11       Impact factor: 28.824

10.  SKP2- and OTUD1-regulated non-proteolytic ubiquitination of YAP promotes YAP nuclear localization and activity.

Authors:  Fan Yao; Zhicheng Zhou; Jongchan Kim; Qinglei Hang; Zhenna Xiao; Baochau N Ton; Liang Chang; Na Liu; Liyong Zeng; Wenqi Wang; Yumeng Wang; Peijing Zhang; Xiaoyu Hu; Xiaohua Su; Han Liang; Yutong Sun; Li Ma
Journal:  Nat Commun       Date:  2018-06-11       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.